Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment | Zendy

Donna K. Arnett | Zendy; Barry R. Davis | Zendy; Charles E. Ford | Zendy; Eric Boerwinkle | Zendy; C LeiendeckerFoster | Zendy; Michael B. Miller | Zendy; Henry R. Black | Zendy; John H. Eckfeldt | Zendy

Open Access

Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment

Author(s) -

Donna K. Arnett,

Barry R. Davis,

Charles E. Ford,

Eric Boerwinkle,

C LeiendeckerFoster,

Michael B. Miller,

Henry R. Black,

John H. Eckfeldt

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.104.504639

Subject(s) - medicine , pharmacogenetics , blood pressure , angiotensin converting enzyme , polymorphism (computer science) , pharmacology , cardiology , renin–angiotensin system , genotype , genetics , gene , biology

Previous studies have reported that blood pressure response to antihypertensive medications is influenced by genetic variation in the renin-angiotensin-aldosterone system, but no clinical trails have tested whether the ACE insertion/deletion (I/D) polymorphism modifies the association between the type of medication and multiple cardiovascular and renal phenotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research